{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 2-(4-Chlorophenyl)-1-[4-[2-(diethylamino)ethoxy]phenyl]-1-(4-methylphenyl)ethanol
| image = Triparanol.svg
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 78-41-1
| CAS_supplemental = 
| ATCvet = 
| ATC_prefix = None
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 6536
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 6288
| UNII = 63S8C3RXGS
| KEGG = 
| ChEBI = 135714
| ChEMBL = 

<!--Chemical data-->
| C=27 | H=32 | Cl=1 | N=1 | O=2
| molecular_weight = 438.00148 g/mol
| smiles = CCN(CC)CCOC1=CC=C(C=C1)C(CC2=CC=C(C=C2)Cl)(C3=CC=C(C=C3)C)O
| StdInChI_Ref = 
| StdInChI = 1S/C27H32ClNO2/c1-4-29(5-2)18-19-31-26-16-12-24(13-17-26)27(30,23-10-6-21(3)7-11-23)20-22-8-14-25(28)15-9-22/h6-17,30H,4-5,18-20H2,1-3H3
| StdInChIKey_Ref = 
| StdInChIKey = SYHDSBBKRLVLFF-UHFFFAOYSA-N
| synonyms = Metasqualene
}}

'''Triparanol''' ([[International Nonproprietary Name|INN]], [[British Approved Name|BAN]]) (brand and developmental code names '''MER/29''', as well as many other brand names), patented in 1959 and introduced in the [[United States]] in 1960,<ref name="Li2009" /><ref name="VanceVance2002">{{cite book|author1=Dennis E. Vance|author2=Jean E. Vance|title=Biochemistry of Lipids, Lipoproteins, and Membranes|url=https://books.google.com/books?id=MQp2AB9QnoMC&pg=PA172|year=2002|publisher=Elsevier|isbn=978-0-444-51138-6|pages=172–174}}</ref> was the first [[Organic compound#Synthetic compounds|synthetic]] [[cholesterol]]-lowering [[drug]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA1252|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=1252–}}</ref><ref name="Ravina2011">{{cite book|author=Enrique Ravina|title=The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs|url=https://books.google.com/books?id=iDNy0XxGqT8C&pg=PA178|date=11 January 2011|publisher=John Wiley & Sons|isbn=978-3-527-32669-3|pages=178–}}</ref> It was [[withdrawn drug|withdrawn]] in 1962 due to severe [[adverse effect]]s such as [[nausea]] and [[vomiting]], [[vision loss]] due to irreversible [[cataracts]], [[alopecia]], [[skin disorder]]s (e.g., [[skin dryness|dryness]], [[itching]], [[skin peeling|peeling]], and "fish-scale" texture), and accelerated [[atherosclerosis]] and is now considered to be obsolete.<ref name="Li2009" /><ref name="Ravina2011" />

The drug acts by inhibiting [[24-dehydrocholesterol reductase]], which catalyzes the final step of cholesterol [[biosynthesis]], the conversion of [[desmosterol]] into cholesterol.<ref name="BurtisAshwood2012">{{cite book|author1=Carl A. Burtis|author2=Edward R. Ashwood|author3=David E. Bruns|title=Tietz Textbook of Clinical Chemistry and Molecular Diagnostics|url=https://books.google.com/books?id=BBLRUI4aHhkC&pg=PA733|date=14 October 2012|publisher=Elsevier Health Sciences|isbn=1-4557-5942-2|pages=733–}}</ref> This results in tissue accumulation of desmosterol, which in turn is responsible for the side effects of triparanol.<ref name="Ravina2011" /> Unlike [[statin]]s, triparanol does not inhibit [[HMG-CoA reductase]], the rate-limiting enzyme in cholesterol biosynthesis,<ref name="Ravina2011" /> and in contrast to triparanol, statins can significantly lower cholesterol levels without resulting in accumulation of intermediates like desmosterol.<ref name="Ravina2011" /> The developmental code name of triparanol, MER/29, became so well-known that it became the registered trade name of the drug.<ref name="Miller1961">{{cite journal|last1=Miller|first1=Lloyd C.|title=Doctors, Drugs, and Names|journal=JAMA|volume=177|issue=1|year=1961|pages=27|issn=0098-7484|doi=10.1001/jama.1961.73040270014004b|quote=Recently, another laboratory code number, MER29, became so well known that it was adopted as the registered trademark for the anticholesterolemic drug concerned (triparanol).}}</ref>

[[Estrogen]] is known to lower cholesterol levels, but produces [[side effect]]s like [[gynecomastia]] and decreased [[libido]] in men.<ref name="Li2009">{{cite book|author=Jie Jack Li|title=Triumph of the Heart: The Story of Statins|url=https://books.google.com/books?id=-GPl1PA5EgMC&pg=PA33|date=3 April 2009|publisher=Oxford University Press, USA|isbn=978-0-19-532357-3|pages=33–}}</ref> It was hoped that a drug could be developed that lacked overt estrogenic effects but still lowered cholesterol levels.<ref name="Li2009" /> Triparanol is a [[triphenylethanol]] and was derived from [[chlorotrianisene]] (TACE), a [[nonsteroidal]] [[triphenylethylene]] estrogen,<ref name="Li2009" /><ref name="GrantSchuman1993">{{cite book|author1=W. Morton Grant|author2=Joel S. Schuman|title=TOXICOLOGY OF THE EYE: Effects on the Eyes and Visual System from Chemicals, Drugs, Metals and Minerals, Plants, Toxins and Venoms; also Systemic Side Effects from Eye Medications (4th Ed.)|url=https://books.google.com/books?id=mDLYCQAAQBAJ&pg=PA384|date=1 January 1993|publisher=Charles C Thomas Publisher|isbn=978-0-398-08215-4|pages=384–}}</ref> and the nonsteroidal triphenylethanol [[antiestrogen]] [[ethamoxytriphetol]] (MER-25) is a derivative of triparanol.<ref name="Manni1999">{{cite book|author=Andrea Manni|title=Endocrinology of Breast Cancer|url=https://books.google.com/books?id=7DSYBwAAQBAJ&pg=PA286|date=15 January 1999|publisher=Springer Science & Business Media|isbn=978-1-59259-699-7|pages=286–}}</ref> The [[selective estrogen receptor modulator]] [[clomifene]] is also structurally related to triparanol.<ref name="GrantSchuman1993" /><ref name="Aronson2009">{{cite book|first=Jeffrey K. |last=Aronson |authorlink=Jeffrey Aronson |title=Meyler's Side Effects of Endocrine and Metabolic Drugs|url=https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA163|date=21 February 2009|publisher=Elsevier|isbn=978-0-08-093292-7|pages=163–}}</ref> The developers of triparanol jokingly referred to it as a "non-estrogenic estrogen".<ref name="Li2009" />

==See also==
* [[Azacosterol]]
* [[Desmosterolosis]]
* [[X-linked ichthyosis]]
* [[Clomestrone]]
* [[Mytatrienediol]]

==References==
{{Reflist|2}}


{{Lipid modifying agents}}

[[Category:24-Dehydrocholesterol reductase inhibitors]]
[[Category:Alcohols]]
[[Category:Amines]]
[[Category:Hypolipidemic agents]]
[[Category:Organochlorides]]
[[Category:Phenol ethers]]
[[Category:Withdrawn drugs]]

{{cardiovascular-drug-stub}}